TTK Healthcare Limited Net Assets
TTK Healthcare Limited net assets. Based on the latest financial reports, TTK Healthcare Limited (TTKHLTCARE) has net assets worth Rs11.15 Billion INR (≈ $120.57 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs13.29 Billion ≈ $143.70 Million USD) and total liabilities (Rs2.14 Billion ≈ $23.13 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore TTK Healthcare Limited annual equity growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs11.15 Billion |
| % of Total Assets | 83.9% |
| Annual Growth Rate | 17.75% |
| 5-Year Change | 238.21% |
| 10-Year Change | 639.13% |
| Growth Volatility | 39.26 |
Net Assets of TTK Healthcare Limited (2005–2026)
Net assets of TTK Healthcare Limited from 2005 to 2026. This chart illustrates how TTK Healthcare Limited's net assets have evolved over time, based on quarterly financial data. See TTKHLTCARE net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for TTK Healthcare Limited (2005–2026)
The table below shows the annual net assets of TTK Healthcare Limited from 2005 to 2026. For live market cap and overall valuation, see TTKHLTCARE market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | Rs11.15 Billion ≈ $120.57 Million |
+4.68% |
| 2025-03-31 | Rs10.65 Billion ≈ $115.18 Million |
+6.41% |
| 2024-03-31 | Rs10.01 Billion ≈ $108.25 Million |
+4.99% |
| 2023-03-31 | Rs9.53 Billion ≈ $103.10 Million |
+189.23% |
| 2022-03-31 | Rs3.30 Billion ≈ $35.65 Million |
+11.87% |
| 2021-03-31 | Rs2.95 Billion ≈ $31.86 Million |
+18.34% |
| 2020-03-31 | Rs2.49 Billion ≈ $26.93 Million |
-0.97% |
| 2019-03-31 | Rs2.51 Billion ≈ $27.19 Million |
+7.92% |
| 2018-03-31 | Rs2.33 Billion ≈ $25.20 Million |
+54.46% |
| 2017-03-31 | Rs1.51 Billion ≈ $16.31 Million |
+10.73% |
| 2016-03-31 | Rs1.36 Billion ≈ $14.73 Million |
+15.17% |
| 2015-03-31 | Rs1.18 Billion ≈ $12.79 Million |
+10.61% |
| 2014-03-31 | Rs1.07 Billion ≈ $11.56 Million |
+8.86% |
| 2013-03-31 | Rs982.22 Million ≈ $10.62 Million |
+11.99% |
| 2012-03-31 | Rs877.03 Million ≈ $9.48 Million |
+15.80% |
| 2011-03-31 | Rs757.35 Million ≈ $8.19 Million |
+17.10% |
| 2010-03-31 | Rs646.73 Million ≈ $6.99 Million |
+4.15% |
| 2009-03-31 | Rs620.96 Million ≈ $6.72 Million |
+8.33% |
| 2008-03-31 | Rs573.23 Million ≈ $6.20 Million |
+19.34% |
| 2007-03-31 | Rs480.31 Million ≈ $5.19 Million |
+31.58% |
| 2006-03-31 | Rs365.03 Million ≈ $3.95 Million |
+1.21% |
| 2005-03-31 | Rs360.68 Million ≈ $3.90 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to TTK Healthcare Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3270.1% over the analyzed period, indicating profitable operations and earnings retention.
TTK Healthcare Limited Net Assets Breakdown (March 2026)
TTK Healthcare Limited net assets breakdown by equity component as of March 2026.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs9.93 Billion | 89.05% |
| Common Stock | Rs141.30 Million | 1.27% |
| Other Comprehensive Income | Rs981.58 Million | 8.80% |
| Other Components | Rs98.25 Million | 0.88% |
| Total Equity | Rs11.15 Billion | 100.00% |
TTK Healthcare Limited Competitors by Market Cap
The table below lists competitors of TTK Healthcare Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Southern Palladium Ltd
AU:SPD
|
$139.98 Million |
|
Wellcall Holdings Bhd
KLSE:7231
|
$140.02 Million |
|
D-Box Technologies Inc.
TO:DBO
|
$140.06 Million |
|
Affinity Bancshares Inc
NASDAQ:AFBI
|
$140.18 Million |
|
Athens Medical C.S.A.
AT:IATR
|
$139.94 Million |
|
Asian Hotels (North) Limited
NSE:ASIANHOTNR
|
$139.91 Million |
|
Kjell Group AB
ST:KJELL
|
$139.90 Million |
|
CVC Ltd
AU:CVC
|
$139.88 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in TTK Healthcare Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 10,650,482,000 to 11,148,504,000, a change of 498,022,000 (4.7%).
- Net income of 656,805,000 contributed positively to equity growth.
- Dividend payments of 141,303,000 reduced retained earnings.
- Other comprehensive income decreased equity by 27,955,999.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs656.80 Million | +5.89% |
| Dividends Paid | Rs141.30 Million | -1.27% |
| Other Comprehensive Income | Rs-27.96 Million | -0.25% |
| Other Changes | Rs10.48 Million | +0.09% |
| Total Change | Rs- | 4.68% |
Book Value vs Market Value Analysis
This analysis compares TTK Healthcare Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.16x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 35.85x to 1.16x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | Rs25.54 | Rs915.75 | x |
| 2006-03-31 | Rs25.85 | Rs915.75 | x |
| 2007-03-31 | Rs34.02 | Rs915.75 | x |
| 2008-03-31 | Rs40.60 | Rs915.75 | x |
| 2009-03-31 | Rs43.98 | Rs915.75 | x |
| 2010-03-31 | Rs45.80 | Rs915.75 | x |
| 2011-03-31 | Rs53.64 | Rs915.75 | x |
| 2012-03-31 | Rs62.11 | Rs915.75 | x |
| 2013-03-31 | Rs69.56 | Rs915.75 | x |
| 2014-03-31 | Rs75.73 | Rs915.75 | x |
| 2015-03-31 | Rs83.76 | Rs915.75 | x |
| 2016-03-31 | Rs96.47 | Rs915.75 | x |
| 2017-03-31 | Rs106.82 | Rs915.75 | x |
| 2018-03-31 | Rs164.88 | Rs915.75 | x |
| 2019-03-31 | Rs177.94 | Rs915.75 | x |
| 2020-03-31 | Rs176.22 | Rs915.75 | x |
| 2021-03-31 | Rs208.53 | Rs915.75 | x |
| 2022-03-31 | Rs233.28 | Rs915.75 | x |
| 2023-03-31 | Rs674.72 | Rs915.75 | x |
| 2024-03-31 | Rs708.36 | Rs915.75 | x |
| 2025-03-31 | Rs753.75 | Rs915.75 | x |
| 2026-03-31 | Rs788.94 | Rs915.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently TTK Healthcare Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.89%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.66%
- • Asset Turnover: 0.65x
- • Equity Multiplier: 1.19x
- Recent ROE (5.89%) is below the historical average (13.56%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -5.74% | -1.35% | 1.65x | 2.58x | Rs-56.77 Million |
| 2006 | 5.49% | 1.07% | 2.04x | 2.51x | Rs-16.47 Million |
| 2007 | 6.25% | 1.42% | 2.05x | 2.15x | Rs-18.02 Million |
| 2008 | 21.26% | 6.12% | 1.67x | 2.08x | Rs64.56 Million |
| 2009 | 12.68% | 3.59% | 1.59x | 2.22x | Rs16.65 Million |
| 2010 | 14.11% | 3.62% | 1.63x | 2.39x | Rs26.60 Million |
| 2011 | 19.44% | 4.74% | 1.60x | 2.55x | Rs71.48 Million |
| 2012 | 17.82% | 4.42% | 1.66x | 2.43x | Rs68.59 Million |
| 2013 | 14.46% | 3.72% | 1.82x | 2.13x | Rs43.81 Million |
| 2014 | 11.59% | 2.98% | 1.73x | 2.24x | Rs16.96 Million |
| 2015 | 13.66% | 3.35% | 1.75x | 2.33x | Rs43.28 Million |
| 2016 | 16.64% | 4.40% | 1.70x | 2.22x | Rs90.44 Million |
| 2017 | 12.82% | 3.65% | 1.85x | 1.90x | Rs42.50 Million |
| 2018 | 7.80% | 3.15% | 1.41x | 1.75x | Rs-51.32 Million |
| 2019 | 9.69% | 3.89% | 1.51x | 1.65x | Rs-7.69 Million |
| 2020 | 4.95% | 1.91% | 1.49x | 1.73x | Rs-125.80 Million |
| 2021 | 15.76% | 9.76% | 0.96x | 1.68x | Rs169.76 Million |
| 2022 | 12.62% | 6.94% | 1.07x | 1.69x | Rs86.25 Million |
| 2023 | 67.10% | 88.22% | 0.62x | 1.23x | Rs5.44 Billion |
| 2024 | 6.28% | 8.41% | 0.62x | 1.20x | Rs-372.50 Million |
| 2025 | 7.67% | 9.36% | 0.68x | 1.20x | Rs-248.48 Million |
| 2026 | 5.89% | 7.66% | 0.65x | 1.19x | Rs-458.05 Million |
Industry Comparison
This section compares TTK Healthcare Limited's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $9,352,691,685
- Average return on equity (ROE) among peers: 25.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| TTK Healthcare Limited (TTKHLTCARE) | Rs11.15 Billion | -5.74% | 0.19x | $139.94 Million |
| GlaxoSmithKline Pharmaceuticals Limited (GLAXO) | $18.21 Billion | 5.12% | 0.72x | $4.72 Billion |
| NGL Fine-Chem Limited (NGLFINE) | $136.48 Million | 19.82% | 0.86x | $171.12 Million |
| Pfizer Limited (PFIZER) | $21.18 Billion | 14.40% | 0.38x | $1.89 Billion |
| Sanofi India Limited (SANOFI) | $4.22 Billion | 35.20% | 0.35x | $842.25 Million |
| SANOFI CONS HEALTHC IND L (SANOFICONR) | $2.73 Billion | 66.30% | 0.58x | $870.71 Million |
| SENORES PHARMACEUTICALS L (SENORES) | $9.65 Billion | 11.96% | 0.66x | $571.27 Million |
About TTK Healthcare Limited
TTK Healthcare Limited engages in the animal welfare, consumer product, medical device, protective device, food, and other businesses in India. It operates through Animal Welfare, Consumer Products, Medical Devices, Foods, Protective Devices and Other segments. The Animal Welfare segment offers various feed supplements, liver correctives, fertility inducers, antibiotics, antiparasiticides, antisp… Read more